...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Archives of dermatological research. >CD164 identifies CD4(+) T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214
【24h】

CD164 identifies CD4(+) T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214

机译：CD164识别与Sezary综合征中的恶性肿瘤相关的CD4（+）T细胞具有高表达基因：SEZARY签名基因，FCRL3，TOX和MIR-214

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sezary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4(+) T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4(+) T cells from Sezary syndrome patients with a wide range of circulating tumor burdens. To further characterize CD164 as a potential biomarker for malignant CD4(+) T cells, CD164(+) and CD164(-)CD4(+) T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1-B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis. The expression of Sezary signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, whereas STAT-4 was lower, in CD164(+) compared with CD164(-)CD4(+) T cells. While Tox was highly expressed in both B2 and B1-B0 patients, the expression of Sezary signature genes, FCRL3, and miR-214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 on circulating CD4(+) T cells from high tumor burden SS patients, further providing strong support for CD164 as a disease relevant surface biomarker.
机译：Sezary综合征（SS）是一种皮肤T细胞淋巴瘤（CTCL）的白血病变体，与皮肤受限制的肌菌诱导相比具有显着较短的寿命。因此，SS的早期诊断是实现增强的治疗反应的关键。然而，在SS患者中缺乏对恶性CD4（+）T细胞的生物标志物对恶性肿瘤的患者进行了严重障碍，以提高诊断。我们最近证明了CD164对CD4（+）T细胞的高表达来自Sezary综合征患者，具有广泛的循环肿瘤负担。进一步表征CD164作为恶性CD4（+）T细胞的潜在生物标志物，CD164（+）和CD164（ - ）CD4（+）T细胞与高循环肿瘤负担，B2阶段和中/低肿瘤分离的患者评估B1-B0阶段的负担，以表达据报道的基因与正常对照区分中的基因，以及与恶性肿瘤和预后不良相关。 Sezary签名基因的表达：T Plastin，GATA-3以及FCR13，TOX和MIR-214显着升高，而STAT-4较低，与CD164（ - ）CD4相比，CD164（+）较低（+ ）T细胞。虽然TOX在B2和B1-B0患者中高度表达，但SEZARY签名基因，FCRL3和MIR-214的表达主要与高级B2疾病相关联。 CTCL患者的皮肤也检测到CD164 mRNA和蛋白质的高表达。 CD164用Kir3DL2与高肿瘤负荷SS患者循环CD4（+）T细胞进行CD164，进一步为CD164作为疾病相关表面生物标志物提供强烈的支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号